Tesamorelin Peptide Guide

Tesamorelin is a growth-hormone-releasing-hormone (GHRH) analog with one specific FDA-approved indication. This page explains what it is and how clinician-supervised programs through ElliotMeds work. It is educational and not medical advice.

Last updated: July 2, 2026

What Is Tesamorelin?

Tesamorelin is a GHRH analog. FDA-approved tesamorelin (Egrifta) is indicated for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Outside that specific approved context, tesamorelin is clinician-reviewed and is not implied to be FDA-approved for general fat loss, bodybuilding, anti-aging, or wellness.

How It Works

Tesamorelin stimulates the pituitary to release growth hormone through the GHRH receptor, which can raise IGF-1. In its approved context it reduces excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It is not the same as directly administering growth hormone.

What It’s Studied For

Tesamorelin is supported by FDA labeling for HIV-associated lipodystrophy and has been studied for visceral-adipose-tissue reduction, effects on IGF-1, glucose-related considerations, and safety concerns such as fluid retention and neoplasm-risk considerations. Body-composition use outside the approved indication is off-label/compounded and is not FDA-approved for that purpose.

Regulatory Status

There is a real FDA-approved tesamorelin product (Egrifta) for one specific indication — HIV-associated lipodystrophy. Use for general body-composition goals is off-label or compounded and does not carry that FDA approval. The approved indication must not be represented as covering general fat-loss use.

What to Expect

Use is provider-directed only; no body-fat or body-composition outcome or timeline is promised outside the approved indication, and effects are individual and unverified for off-label use.

Preferred Starting Options / Dosing Notes

Many patients begin with a lower starting option so a licensed clinician can evaluate tolerance, medical history, goals, and safety factors before any adjustments are considered. The starting option shown below is informational and reflects available program data, not self-directed dosing instructions. Final medication, dose, frequency, and treatment plan are determined by a licensed clinician.

Safety Considerations

• Reported risks include increased risk of neoplasms and elevated IGF-1; fluid retention, glucose intolerance or diabetes mellitus, hypersensitivity, and injection-site reactions; and contraindication in pregnancy for the labeled product context.
• No peptide is "safe" without qualification.

Who Is Not a Candidate

Active malignancy, pregnancy, disruption of the pituitary/HPA axis, uncontrolled diabetes, or significant fluid retention require careful review; a clinician also reviews goals, metabolic status, IGF-1 concerns, and medications, and may determine it is not appropriate.

How It Compares

Tesamorelin is a GHRH analog with an FDA-approved indication; sermorelin and CJC-1295 are other GH-axis peptides without that approval. None is presented as superior for off-label goals, and a clinician determines what, if anything, fits.

Frequently Asked Questions

References

• FDA Prescribing Information — Egrifta / Egrifta SV / Egrifta WR (tesamorelin)
• peer-reviewed literature on tesamorelin (PubMed)